Cargando…

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial

OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management o...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzyzanowska, Monika K, Julian, Jim A, Gu, Chu-Shu, Powis, Melanie, Li, Qing, Enright, Katherine, Howell, Doris, Earle, Craig C, Gandhi, Sonal, Rask, Sara, Brezden-Masley, Christine, Dent, Susan, Hajra, Leena, Freeman, Orit, Spadafora, Silvana, Hamm, Caroline, Califaretti, Nadia, Trudeau, Maureen, Levine, Mark N, Amir, Eitan, Bordeleau, Louise, Chiarotto, James A, Elser, Christine, Husain, Juhi, Laferriere, Nicole, Rahim, Yasmin, Robinson, Andrew G, Vandenberg, Ted, Grunfeld, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652580/
https://www.ncbi.nlm.nih.gov/pubmed/34880055
http://dx.doi.org/10.1136/bmj-2021-066588
_version_ 1784611599361769472
author Krzyzanowska, Monika K
Julian, Jim A
Gu, Chu-Shu
Powis, Melanie
Li, Qing
Enright, Katherine
Howell, Doris
Earle, Craig C
Gandhi, Sonal
Rask, Sara
Brezden-Masley, Christine
Dent, Susan
Hajra, Leena
Freeman, Orit
Spadafora, Silvana
Hamm, Caroline
Califaretti, Nadia
Trudeau, Maureen
Levine, Mark N
Amir, Eitan
Bordeleau, Louise
Chiarotto, James A
Elser, Christine
Husain, Juhi
Laferriere, Nicole
Rahim, Yasmin
Robinson, Andrew G
Vandenberg, Ted
Grunfeld, Eva
author_facet Krzyzanowska, Monika K
Julian, Jim A
Gu, Chu-Shu
Powis, Melanie
Li, Qing
Enright, Katherine
Howell, Doris
Earle, Craig C
Gandhi, Sonal
Rask, Sara
Brezden-Masley, Christine
Dent, Susan
Hajra, Leena
Freeman, Orit
Spadafora, Silvana
Hamm, Caroline
Califaretti, Nadia
Trudeau, Maureen
Levine, Mark N
Amir, Eitan
Bordeleau, Louise
Chiarotto, James A
Elser, Christine
Husain, Juhi
Laferriere, Nicole
Rahim, Yasmin
Robinson, Andrew G
Vandenberg, Ted
Grunfeld, Eva
author_sort Krzyzanowska, Monika K
collection PubMed
description OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management of toxicities or routine care. PARTICIPANTS: All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre. 25 patients from each centre completed patient reported outcome questionnaires. INTERVENTIONS: Proactive, standardised, nurse led telephone management of common toxicities at two time points after each chemotherapy cycle. MAIN OUTCOME MEASURES: The primary outcome, cluster level mean number of visits to the emergency department or admissions to hospital per patient during the whole course of chemotherapy treatment, was evaluated with routinely available administrative healthcare data. Secondary patient reported outcomes included toxicity, self-efficacy, and quality of life. RESULTS: Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. Penetration (that is, the percentage of patients who received the intervention at each centre) was 50-86%. Mean number of visits to the emergency department or admissions to hospital per patient was 0.91 (standard deviation 0.28) in the intervention arm and 0.94 (0.40) in the control arm (P=0.94); 47% (1014 of 2158 patients) had at least one visit to the emergency department or a hospital admission during chemotherapy. Among 580 participants who completed the patient reported outcome questionnaires, at least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm. No differences in self-efficacy, anxiety, or depression were found. Compared with baseline, the functional assessment of cancer therapy trial outcome index decreased by 6.1 and 9.0 points in the intervention and control participants, respectively. CONCLUSIONS: Proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or hospital admissions. With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant. TRIAL REGISTRATION: ClinicalTrials.gov NCT02485678.
format Online
Article
Text
id pubmed-8652580
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-86525802021-12-22 Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial Krzyzanowska, Monika K Julian, Jim A Gu, Chu-Shu Powis, Melanie Li, Qing Enright, Katherine Howell, Doris Earle, Craig C Gandhi, Sonal Rask, Sara Brezden-Masley, Christine Dent, Susan Hajra, Leena Freeman, Orit Spadafora, Silvana Hamm, Caroline Califaretti, Nadia Trudeau, Maureen Levine, Mark N Amir, Eitan Bordeleau, Louise Chiarotto, James A Elser, Christine Husain, Juhi Laferriere, Nicole Rahim, Yasmin Robinson, Andrew G Vandenberg, Ted Grunfeld, Eva BMJ Research OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management of toxicities or routine care. PARTICIPANTS: All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre. 25 patients from each centre completed patient reported outcome questionnaires. INTERVENTIONS: Proactive, standardised, nurse led telephone management of common toxicities at two time points after each chemotherapy cycle. MAIN OUTCOME MEASURES: The primary outcome, cluster level mean number of visits to the emergency department or admissions to hospital per patient during the whole course of chemotherapy treatment, was evaluated with routinely available administrative healthcare data. Secondary patient reported outcomes included toxicity, self-efficacy, and quality of life. RESULTS: Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. Penetration (that is, the percentage of patients who received the intervention at each centre) was 50-86%. Mean number of visits to the emergency department or admissions to hospital per patient was 0.91 (standard deviation 0.28) in the intervention arm and 0.94 (0.40) in the control arm (P=0.94); 47% (1014 of 2158 patients) had at least one visit to the emergency department or a hospital admission during chemotherapy. Among 580 participants who completed the patient reported outcome questionnaires, at least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm. No differences in self-efficacy, anxiety, or depression were found. Compared with baseline, the functional assessment of cancer therapy trial outcome index decreased by 6.1 and 9.0 points in the intervention and control participants, respectively. CONCLUSIONS: Proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or hospital admissions. With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant. TRIAL REGISTRATION: ClinicalTrials.gov NCT02485678. BMJ Publishing Group Ltd. 2021-12-08 /pmc/articles/PMC8652580/ /pubmed/34880055 http://dx.doi.org/10.1136/bmj-2021-066588 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Krzyzanowska, Monika K
Julian, Jim A
Gu, Chu-Shu
Powis, Melanie
Li, Qing
Enright, Katherine
Howell, Doris
Earle, Craig C
Gandhi, Sonal
Rask, Sara
Brezden-Masley, Christine
Dent, Susan
Hajra, Leena
Freeman, Orit
Spadafora, Silvana
Hamm, Caroline
Califaretti, Nadia
Trudeau, Maureen
Levine, Mark N
Amir, Eitan
Bordeleau, Louise
Chiarotto, James A
Elser, Christine
Husain, Juhi
Laferriere, Nicole
Rahim, Yasmin
Robinson, Andrew G
Vandenberg, Ted
Grunfeld, Eva
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
title Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
title_full Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
title_fullStr Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
title_full_unstemmed Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
title_short Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
title_sort remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652580/
https://www.ncbi.nlm.nih.gov/pubmed/34880055
http://dx.doi.org/10.1136/bmj-2021-066588
work_keys_str_mv AT krzyzanowskamonikak remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT julianjima remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT guchushu remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT powismelanie remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT liqing remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT enrightkatherine remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT howelldoris remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT earlecraigc remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT gandhisonal remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT rasksara remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT brezdenmasleychristine remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT dentsusan remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT hajraleena remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT freemanorit remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT spadaforasilvana remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT hammcaroline remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT califarettinadia remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT trudeaumaureen remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT levinemarkn remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT amireitan remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT bordeleaulouise remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT chiarottojamesa remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT elserchristine remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT husainjuhi remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT laferrierenicole remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT rahimyasmin remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT robinsonandrewg remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT vandenbergted remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial
AT grunfeldeva remoteproactivetelephonebasedmanagementoftoxicityinoutpatientsduringadjuvantorneoadjuvantchemotherapyforearlystagebreastcancerpragmaticclusterrandomisedtrial